- Open
- 437.50
- High
- 445.00
- Low
- 430.00
- Close
- 433.75
- Change
- -6.00 (-1.38%)
- Volume
- 28,126
| 30 Sept 2026 | 07:00:08 | Notice of Results |
| 11 Aug 2026 | 14:55:42 | Exercise of Share Options and Total Voting Rights |
| 31 Jul 2026 | 10:05:21 | Exercise of Share Options and Total Voting Rights |
| 27 Jul 2026 | 07:00:09 | 3T Pro commercial launch |
| 30 Oct 2025 | Annual Report and Accounts (to 2025-06-30) | |
| 16 Dec 2024 | Annual Report and Accounts (to 2024-06-30) | |
| 22 Dec 2023 | Annual Report and Accounts (to 2023-06-30) |
| 2 Mar 2026 | Find out how Tristel could ‘clean up’ in the US | |
| 22 Jan 2026 | Tristel confirms FY outlook | |
Tristel plc develops and manufactures infection control products, primarily focusing on the healthcare sector. The company offers a range of disinfectants and sterilants that are used in hospitals and other medical facilities to maintain hygiene and prevent contamination. Tristel operates mainly in the United Kingdom and has a growing international presence, with significant sales in Europe and the Asia-Pacific region. Its business model relies on direct sales and a network of distributors to reach various healthcare customers globally.
| 30 Sept 2026 | 07:00:08 | Notice of Results |
| 11 Aug 2026 | 14:55:42 | Exercise of Share Options and Total Voting Rights |
| 31 Jul 2026 | 10:05:21 | Exercise of Share Options and Total Voting Rights |
| 27 Jul 2026 | 07:00:09 | 3T Pro commercial launch |
| 30 Oct 2025 | Annual Report and Accounts (to 2025-06-30) | |
| 16 Dec 2024 | Annual Report and Accounts (to 2024-06-30) | |
| 22 Dec 2023 | Annual Report and Accounts (to 2023-06-30) |
| 2 Mar 2026 | Find out how Tristel could ‘clean up’ in the US | |
| 22 Jan 2026 | Tristel confirms FY outlook | |
Tristel plc develops and manufactures infection control products, primarily focusing on the healthcare sector. The company offers a range of disinfectants and sterilants that are used in hospitals and other medical facilities to maintain hygiene and prevent contamination. Tristel operates mainly in the United Kingdom and has a growing international presence, with significant sales in Europe and the Asia-Pacific region. Its business model relies on direct sales and a network of distributors to reach various healthcare customers globally.
| 22 Jul 2026 | 07:00:01 | Positive Trading Update |
| 22 Jan 2026 |
| Tristel reveals strong start to year |
| 22 Jul 2026 | 07:00:01 | Positive Trading Update |
| 22 Jan 2026 |
| Tristel reveals strong start to year |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £619m | +0.2% | |
| £284m | -0.1% | |
TSTLTristel plc | £209m | +0.2% |
| £104m | +0.1% | |
| £81m | +0.3% | |
| £55m | -0.3% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £619m | +0.2% | |
| £284m | -0.1% | |
TSTLTristel plc | £209m | +0.2% |
| £104m | +0.1% | |
| £81m | +0.3% | |
| £55m | -0.3% |